Conclusions
bleeding, ASCVD
SECONDARY, ASCVD, BLEEDING
In this post hoc secondary analysis of data from the ADAPTABLE randomized clinical trial, there were no significant differences in the primary effectiveness or safety end points between enteric-coated aspirin and uncoated aspirin among participants with established ASCVD although a reduction in bleeding with enteric-coated aspirin cannot be reliably excluded. More research is needed to confirm whether enteric-coated aspirin formulations or newer formulations will improve ischemic and bleeding outcomes among patients with ASCVD.